SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN
PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16
UNDER THE SECURITIES
EXCHANGE ACT OF 1934
June, 2024
Commission File
Number 1-15182
DR.
REDDY’S LABORATORIES LIMITED
(Translation of registrant’s name into English)
8-2-337, Road No. 3, Banjara Hills
Hyderabad, Telangana 500 034, India
+91-40-49002900
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F x Form
40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in
paper as permitted by Regulation S-T Rule 101(b)(1): ______
Note: Regulation S-T Rule 101(b)(1) only permits the submission
in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in
paper as permitted by Regulation S-T Rule 101(b)(7): ______
Note: Regulation S-T Rule 101(b)(7) only permits
the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must
furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the
registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities
are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the
registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other
Commission filing on EDGAR.
Indicate by check mark whether by furnishing the
information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b)
under the Securities Exchange Act of 1934.
Yes
¨ No
x
If “Yes” is marked, indicate below the file number assigned
to registrant in connection with Rule 12g3-2(b): 82-________.
EXHIBITS
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
DR.
REDDY’S LABORATORIES LIMITED (Registrant) |
|
|
|
Date: June 03, 2024 |
By: |
/s/
K Randhir Singh |
|
|
Name: |
K
Randhir Singh |
|
|
Title: |
Company
Secretary |
Exhibit 99.1
|
Dr. Reddy’s Laboratories Ltd.
8-2-337, Road No. 3, Banjara Hills,
Hyderabad - 500 034, Telangana,
India.
CIN : L85195TG1984PLC004507
Tel : +91 40 4900 2900
Fax : +91 40 4900 2999
Email : mail@drreddys.com
www.drreddys.com |
June
3, 2024
National
Stock Exchange of India Ltd. (Stock Code: DRREDDY-EQ)
BSE
Limited (Stock Code: 500124)
New
York Stock Exchange Inc. (Stock Code: RDY)
NSE
IFSC Ltd. (Stock Code: DRREDDY)
Dear
Sir/Madam,
Sub:
Press Release
Please
find enclosed a Press Release on “Aurigene Pharmaceutical Services Limited, a global CRDMO, announces the opening of its biologics
facility offering process development and clinical scale manufacturing capabilities”. Aurigene Pharmaceutical Services Limited
is a step down wholly owned subsidiary of the Company.
This
is for your information and record.
Thanking
you.
Yours
faithfully,
For
Dr. Reddy’s Laboratories Limited
K
Randhir Singh
Company
Secretary, Compliance Officer & Head-CSR
Encl:
As above
Press
release
Aurigene
Pharmaceutical Services Limited, a global CRDMO, announces the opening of its biologics facility offering process development and clinical
scale manufacturing capabilities
Hyderabad,
India- June 03, 2024: Aurigene Pharmaceutical Services Limited (“Aurigene”), a Dr. Reddy’s Laboratories Limited
company, inaugurated its biologics facility spread across 70,000 sq.ft. in Genome Valley, a bio cluster, located in Hyderabad, India.
The facility is designed to serve customers with process & analytical development and small scale manufacturing of antibodies and
other recombinant proteins for preclinical and early phase clinical requirements. The process and analytical development laboratories
are now operational while the commissioning of manufacturing capacity will be completed later in 2024.
The
state-of-the-art facility is equipped with best-in-class equipment and control systems, supported by an experienced talent pool that
will ensure seamless transfer to large-scale commercial CGMP manufacturing facilities. The new facility is complementary to the company’s
current discovery capabilities and infrastructure, which primarily focuses on recombinant proteins including mAbs, bi- and multi-specifics,
immune-fusion molecules, antibody drug conjugates and other complex proteins.
Aurigene’s
comprehensive end-to-end service offering now delivers solutions from, discovery through large-scale commercial manufacturing from three
proximally located campuses (discovery, process development/clinical manufacture and large scale commercial manufacture) thus ensuring
seamless delivery from “concept to commercial”. The newly opened Genome Valley facility will deliver robust, compliant and
economically viable cell lines, process development solutions and supporting analytical methods in support of customers seeking to rapidly
enter and progress through clinical development.
The
opening of this latest facility is one of multiple strategic initiatives that Aurigene is implementing to support rapid growth in both
the small molecule and biologics spaces, as illustrated by recent announcements related to AI/ML-led drug discovery in small molecules
and a collaboration with Vipergen, a DNA-encoded library (DEL) technologies service provider.
Akhil
Ravi, CEO, Aurigene, commented, “The journey started a year back when we decided to invest in creating the facility. It is
great to see the facility operational and the addition of this capacity and capabilities shows our firm commitment to the continued expansion
of our biologics business, building on 25 years of proven experience. The state-of-the-art facility will enable us to service our global
customers efficiently and support in the development of innovative medicine.”
Dr.
Roger Lias, Global Commercial Head – Biologics, Aurigene, added, “There are very few global CDMOs that can truly support
customers “end-to-end” from discovery services to large scale commercial manufacture of both Drug Substance and Drug Product.
Our new facility further strengthens Aurigene’s capabilities and builds on our technical excellence, demonstrated global compliance
and state-of-the-art facilities as companies from start-up biotechs to global multinationals continue to strengthen their supply chains
and seek economically viable support for both their development portfolios and marketed products.”
About
Aurigene:
Aurigene
is a global contract research, development, and manufacturing organization (CRDMO) – a Dr. Reddy’s company - built on the
legacy of accelerating innovation and backed by a vast experience in drug discovery, development, and manufacturing of biologics and
small molecules. Aurigene offers integrated and standalone services for biotherapeutics discovery, discovery chemistry, discovery biology,
development and manufacturing services for clinical phase I-III programs, regulatory submission batches and commercial manufacturing.
For
more information log on to: https://www.aurigeneservices.com/ or email us at: ContactAPSL@aurigeneservices.com LinkedIn YouTube
| |
About
Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical
company headquartered in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines.
Driven by our purpose of ‘Good Health Can’t Wait’, we offer a portfolio of products and services including APIs, generics,
branded generics, biosimilars and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology,
pain management and dermatology. Our major markets include – USA, India, Russia & CIS countries, China, Brazil, and Europe.
As a company with a history of deep science that has led to several industry firsts, we continue to plan and invest in businesses of
the future. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG
goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance.
CONTACTS
Usha
Iyer
Head
of Corporate Communications
ushaiyer@drreddys.com |
Richa
Periwal
Head
of Investor Relations
richaperiwal@drreddys.com |
Dr Reddys Laboratories (NYSE:RDY)
過去 株価チャート
から 5 2024 まで 6 2024
Dr Reddys Laboratories (NYSE:RDY)
過去 株価チャート
から 6 2023 まで 6 2024